HOUSTON, March 19, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks Small-Cap Research. REGISTER NOW AT: https://bit.ly/3T80zZl The company presentations will be available 24/7 for 90
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/430WqL8It is recomm